Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Up 11.6%
Xenon Pharmaceuticals Inc (NASDAQ:XENE)’s stock price rose 11.6% during trading on Wednesday . The stock traded as high as $17.40 and last traded at $17.18, approximately 553,058 shares changed hands during trading. An increase of 70% from the average daily volume of 324,642 shares. The stock had previously closed at $15.40.
XENE has been the subject of several research reports. BidaskClub downgraded shares of Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 4th. ValuEngine downgraded shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. William Blair initiated coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, January 8th. They set an “outperform” rating for the company. Finally, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $16.00 price objective for the company in a research note on Saturday, January 11th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Xenon Pharmaceuticals has an average rating of “Buy” and an average target price of $19.67.
The company has a debt-to-equity ratio of 0.18, a current ratio of 8.25 and a quick ratio of 8.25. The company’s fifty day moving average is $15.31 and its 200-day moving average is $11.25. The stock has a market cap of $437.45 million, a PE ratio of -11.99 and a beta of 1.50.
About Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Recommended Story: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.